Molecular Therapies of Cancer

Georg Weber, MD, PhD, is Associate Professor at the James L. Winkle College of Pharmacy at the University of Cincinnati. Dr. Weber has made contributions to metastasis research by discovering the interaction between the molecules osteopontin and CD44 and by defining the physiologic role of metastasis genes as stress response genes. While he continues to address fundamental questions, he is researching new venues for diagnosis and therapy of cancer progression. Dr. Weber's professional affiliations include the American Association for the Advancement of Science, American Medical Association, American Association for Cancer Research, and Metastasis Research Society. Dr. Weber has published several books including Molecular Mechanisms of Cancer, which was published by Springer.

lt;p>INTRODUCTION

SECTION I: GENERAL PRINCIPLES

SECTION II: MOLECULAR TARGETING OF CANCER CELLS

1. DNA DAMAGING DRUGS
1.1. ALKYLATING AGENTS
1.2. ANTIBIOTICS
1.3. TOPOISOMERASE INHIBITORS
1.4. ANTI-METABOLITES

2. DRUGS THAT SUPPRESS PROLIFERATION
2.1. ANTI-MITOTIC AGENTS
2.2. DIFFERENTIATING AGENTS
2.3. INDUCERS OF APOPTOSIS

3. MOLECULAR INHIBITORS OF GROWTH SIGNALS
3.1. SMALL MOLECULE KINASE INHIBITORS
3.2. INHIBITORS OF ONCOGENE FUNCTIONS
3.3. ANTIBODIES

4. ANTI-METASTASIS THERAPY
4.1. INTEGRIN INHIBITORS
4.2. CD44 INHIBITORS
4.3. MMP INHIBITORS
4.4. CHEMOKINE RECEPTOR INHIBITORS
4.5. TGF- IHIBITORS
4.6. BONE TARGETING AGENTS
4.7. OTHERS

5. INDUCTION OF SENESCENCE
5.1. TELOMERASE INHIBITORS

6. COMBINATION CHEMOTHERAPY
6.1. TREATMENT OF HEMATOLOGIC MALIGNANCIES
6.2. TREATMENT OF SOLID TUMORS

SECTION III: EMERGING AND ALTERNATIVE TREATMENT MODALITIES

7. GENE THERAPY
7.1. GENE SILENCING
7.2. SUICIDE GENES
7.3. ONCOLYTIC VIRUSES
7.4. GENE DELIVERY
7.5. OTHER STRATEGIES

8. DRUGS WITH DIVERSE MODES OF ACTION

SECTION IV: MOLECULAR TARGETING OF TUMOR-HOST INTERACTIONS

9. HORMONE THERAPY
9.1. ANTI-ESTROGENS
9.2. ANTI-ANDROGENS
9.3. CORTICOSTEROIDS

10. IMMUNOTHERAPY
10.1. IMMUNOTOXINS
10.2. ENGINEERED ANTIBODIES
10.3. ANTIGEN BASED IMMUNOTHERAPIES
10.4. CYTOKINE BASED IMMUNOTHERAPIES
10.5. IMMUNE RESPONSE MODIFIERS
10.6. AUTOLOGOUS THERAPIES
10.7. OTHER REGIMENS

11. ANTI-ANGIOGENESIS
11.1. VEGF ANTAGONISTS
11.2. FGF-2 ANTAGONISTS
11.3. THALIDOMIDE RELATED DRUGS
11.4. INTEGRIN BLOCKERS
11.5. ENDOSTATIN AND ANGIOSTATIN
11.6. OTHERS

SECTION V: ANTI-CANCER DRUG PHARMACOKINETICS

12. DRUG DELIVERY AND DRUG TRANSPORT
12.1. TARGETING WITH DRUG CONJUGATES
12.2.

13. DRUG METABOLISM
13.1. CYP450
13.2. FLAVIN MONOOXYGENASES
13.3. GST
13.4. OTHERS

14. PRODRUG ACTIVATION
14.1. PHOTODYNAMIC THERAPY
14.2. RADIO-SENSITIZATION

15. DRUG RESISTANCE
15.1. INCREASED EFFLUX
15.2. DECREASED UPTAKE
15.3. ANTI-APOPTOSIS
15.4. MUTATIONS IN THE DRUG TARGET
15.5. ALTERED REPAIR OF DRUG INDUCED DAMAGE
15.6. OTHER MECHANISMS

SECTION VI: SUPPORTIVE THERAPY

16. PROTECTION FROM ADVERSE EFFECTS
16.1. ANTI-EMETICS
16.2. PROTECTION FROM ANEMIA
16.3. IMMUNE RECOVERY
16.4. CARDIOVASCULAR PROTECTION
16.5. ANTI-OXIDANTS
16.6. ANTI-CACHEXIA DRUGS
16.7. PROTECTION FROM HEPATOTOXICITY
16.8. PROTECTION FROM URINARY TOXICITY
16.9. PROTECTION OF THE GASTROINTESTINAL TRACT
16.10. TREATMENT OF DERMATOLOGIC REACTIONS TO CHEMOTHERAPY
16.11. ELECTROLYTE BALANCE
16.12. REPRODUCTIVE PROTECTION
16.13. OTHERS

17. PAIN MANAGEMENT
17.1. NON-STEROIDAL DRUGS
17.2. OPIOID DRUGS
17.3. OTHERS

18. PREVENTIVE TREATMENT
18.1. VACCINES
18.2. CHEMOPREVENTION